Paget’s Disease of Bone

  • Roy D. Altman


  • Paget’s disease affects 1% of the US population over the age of 40 years and is a chronic disorder of adult skeleton characterized by increased resorption and deposition of bone resulting in replacement of the normal matrix with softened and enlarged bone.

  • Most adults with Paget’s disease are asymptomatic and diagnosis is found on x-ray of the bones.

  • Bone pain, fracture, and nerve impingement can occur due to enlarging and poorly constructed bone matrix.

  • ■ Potent and generally safe suppressive agents have been developed and have resulted in a more aggressive approach to therapy.


Hearing Loss Zoledronic Acid Bone Pain Salmon Calcitonin Disodium Etidronate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Altman RD, Bloch DA, Hochberg MC, Murphy WA. Prevalence of pelvic Paget’s disease of bone in the United States. J Bone Miner Res 2000;15:461–465.PubMedCrossRefGoogle Scholar
  2. 2.
    Michou L, Collet C, Laplanche JL, Orcel P, Cornelis F. Genetics of Paget’s disease of bone. Joint Bone Spine 2006;73:243–248.PubMedCrossRefGoogle Scholar
  3. 3.
    Kurihara N, Zhou H, Reddy SV, et al. Expression of measles virus nucleocapsid protein in Osteoclasts induces Paget’s disease-like bone lesions in mice. J Bone Miner Res 2006;21:446–455.PubMedCrossRefGoogle Scholar
  4. 4.
    Altman RD. Musculoskeletal manifestations of Paget’s disease of bone. Arthritis Rheum 1980;23:1121–1127.PubMedCrossRefGoogle Scholar
  5. 5.
    Woo S-B, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaw. Ann Intern Med 2006;144:753–761.Google Scholar
  6. 6.
    Walsh JP, Ward LC, Stewart GO, et al. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget’s disease of bone. Bone 2004;34:747–754.PubMedCrossRefGoogle Scholar
  7. 7.
    Altman RD, Johnston CC, Khairi MRA, Wellman H, Serafi ni AN, Sankey RR. Influence of disodium etidronate on clinical and laboratory manifestations of Paget’s disease of bone (osteitis deformans). N Engl J Med 1973;289:1379–1384.PubMedCrossRefGoogle Scholar
  8. 8.
    Vasireddy S. Talwalkar A, Miller H, Mehan R, Swinson DR. Patterns of pain in Paget’s disease of bone and their outcomes on treatment with pamidronate. Clin Rheumatol 2003;22:376–380.PubMedCrossRefGoogle Scholar
  9. 9.
    Crandall C. Risedronate: a clinical review. Arch Intern Med 2001;161:353–360.PubMedCrossRefGoogle Scholar
  10. 10.
    Morales-Piga A. Tiludronate. A new treatment for an old ailment: Paget’s disease of bone. Expert Opin Pharmacother 1999;1:157–170.PubMedCrossRefGoogle Scholar
  11. 11.
    Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med 2005;353:898–908.PubMedCrossRefGoogle Scholar
  12. 12.
    Martin TJ. Treatment of Paget’s disease with calcitonins. Aust N Z J Med 1979;9:36–43.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Roy D. Altman
    • 1
  1. 1.Deparment of Medicine/Rheumatology and ImmunologyUniversity of CaliforniaLos Angeles, Los AngelesUSA

Personalised recommendations